Popular Articles

Diagnosing Gastro-related Disease Becomes Even Simpler
Given Imaging LTD. (NASDAQ: GIVN) announced the launch of a simplified procedure for performing PillCam SB 2 capsule endoscopies for the detection of disease in the small intestine. Unveiled at the Society of Gastroenterology Nurses and Associates, Inc. (SGNA) 36th Annual Course, the new procedure utilizes two new products - SensorBelt and RecorderPouch - replacing the sensor array and the recorder belt used previously with the DataRecorder to record the wireless signals emitted by the capsule. Both products can be viewed at Given Imaging"s booth #623 at the SGNA meeting, taking place in St. Louis from May 15 to May 20.
pharmacy online
MAP Pharmaceuticals Phase 3 Trial Of Levadex™ Migraine Product Candidate Meets All Four Primary Endpoints
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX™ orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
News of the day
Review Of Brazil's HIV/AIDS Treatment Programs Shows Importance Of Generic Drugs, Researchers Say
"Brazil has been successful in its nearly 20-year effort to treat people living with" HIV/AIDS, and generic medicines have been "a large part of the solution," according to a recent Health Affairs review, UPI reports (UPI, 7/14). The review examines Brazil"s passing of "a law in the 1990s that guaranteed citizens free and universal access to drugs for HIV and AIDS treatment" as well as the country"s production of generic HIV/AIDS medicines in public factories, AHN reports. "The [Brazilian] government also prompted drug companies to lower their prices by threatening to make generic versions of [patented] HIV and AIDS drugs in the public factories," writes AHN (Goodhue, 7/14).
Nutrition

Cambridge Consultants To Showcase Inhaler Design And Development Process At RDD 2009, Europe

Cambridge Consultants will be showcasing its proprietary design and development process for Dry Power Inhalers (DPIs) at the Respiratory Drug Delivery (RDD) Europe 2009 conference in Lisbon later this month.÷  The company will demonstrate its ability to move inhaler design quickly through all stages of development from concept through manufacture to final product, getting it right first time, accelerating the creation of new inhalable drug delivery devices, and offering pharmaceutical companies a quick route to market, saving up to six months in development. "Our RDD presence is all about the importance of speed to market, and this demonstration is designed to highlight the range of development capabilities we can deploy to achieve it for our clients," commented David Blakey, Head of Drug Delivery at Cambridge Consultants.÷  "It is crucial to ensure process quality in stages such as concept creation, complex mathematical modelling and detailed design.÷  These are areas where Cambridge Consultants adds significant value, based on our skill and experience in running turn key developments, from concept to clinical trial and through transfer to manufacture." Cambridge Consultants will be using Gen-X, a proprietary DPI, to demonstrate the key stages in the design cycle.÷  The display tracks the stages of the process up to the test bed stage, where the efficacy of the de-aggregation engine has been tested.÷  Cambridge Consultants is currently selecting development partners to take this concept to market. David Blakey adds: "Supported by our proprietary design and development process, our partners can cut up to six months off the development cycle for DPIs, giving them a significant head start and reducing development risk." The demonstration of Cambridge Consultants" product development process will be available on Cambridge Consultants" stand at the Respiratory Drug Delivery Europe 2009 conference in Lisbon, Portugal, from 19-22 May. Cambridge Consultants


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):